nash semaglutide Phase 3 Trial of in Metabolic Dysfunction–Associated Steatohepatitis Semaglutide initiates Phase III clinical
Description
Additionally, GLP-1 slows down digestion and helping you feel fuller for longer
Structure Therapeutics is a smaller biotech company
Among patients also receiving metformin immediate-release, the median daily insulin (pre-mixed, intermediate or long acting) dose at baseline was 40 units in the sitagliptin-treated patients and 42 units in the placebo-treated patients
FDA approval is expected in 2025-2026 if trials are successful
These include oral medications like phentermine, phentermine-topiramate, bupropion-naltrexone, and others
